New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 21, 2014
09:21 EDTAZN, TEVA, MNTA, CBEY, ATHN, ACTG, AMD, ABX, NEM, NUS, RNA, SRPT, PFE, MUOn The Fly: Pre-Market Movers
HIGHER: Sarepta (SRPT), up 54% after announcing plans to to submit NDA for Eteplirsen by year end 2014. Shares of Prosnesa (RNA), another drugmaker working on a competing DMD drug, are up more than 12%... AstraZeneca (AZN), up 6% after the Sunday Times says that Pfizer (PFE) is considering a takeover bid for the company. Pfizer is up 1.2% following the report... Newmont Mining (NEM), up 8% after WSJ says the company and Barrick Gold (ABX) could resume merger talks as soon as today... Cbeyond (CBEY), up 39% after agreeing to be acquired for about $323M by Birch Communications... Momenta Pharma (MNTA), up 10.5% after the Supreme Court rejected Teva's (TEVA) bid to delay generic Copaxone... Nu Skin (NUS), up 5% after saying its China division will resume corporate-hosted business meetings... Micron (MU), up 4% after price target raised at Drexel Hamilton... DOWN AFTER EARNINGS: Acacia Research (ACTG), down 6%... athenahealth (ATHN), down 5.6%.
News For AZN;PFE;SRPT;RNA;NUS;NEM;ABX;AMD;ACTG;ATHN;CBEY;MNTA;TEVA;MU From The Last 14 Days
Check below for free stories on AZN;PFE;SRPT;RNA;NUS;NEM;ABX;AMD;ACTG;ATHN;CBEY;MNTA;TEVA;MU the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
September 14, 2014
13:32 EDTPFEPfizer shares look cheap, Barron's says
Subscribe for More Information
September 12, 2014
10:32 EDTAZN, PFEPfizer CEO says company still open to inversion deal, FT says
Pfizer (PFE) CEO Ian Read said U.S. rhetoric against tax inversions has been "political theater" ahead of midterm elections and made clear that his company is still open to a potential tax-saving acquisition, according to Financial Times, which added Read's comment about not being “held hostage” over price would likely be read as a signal the company might look elsewhere after being rebuffed by AstraZeneca (AZN). The Fly notes that Bloomberg previously reported, citing people familiar with the matter, that Pfizer is looking at targets other than AstraZeneca, including Actavis (ACT). Shares of Actavis trading in New York are up 2% this morning. Reference Link
09:01 EDTTEVATeva to present Copaxone gene expression analysis
Subscribe for More Information
08:06 EDTTEVATeva presents new clinical safety data in RRMS patients treated with Laquinimod
Teva (TEVA) and Active Biotech (ACTI) announced new follow-up data evaluating the clinical safety of laquinimod in patients with relapsing-remitting multiple sclerosis, or RRMS, who were treated with laquinimod in Phase II, Phase III and open-label extension studies for two or more years. The pooled safety analysis of the Phase II LAQ/5063 and the Phase III ALLEGRO and BRAVO extension studies supports findings observed in the core studies where currently identified risks were observed within the first months of laquinimod treatment. In the pooled safety analysis, rates of adverse events, or AEs, and serious AEs were lower in the open-label extensions than in the core studies and less than three percent of patients discontinued treatment due to AEs during these extensions. Additionally, shifts to potentially significant laboratory values were considerably lower in patients exposed to at least two years of laquinimod.
08:03 EDTTEVATeva, Active Biotech present laquinimod follow-up data
Subscribe for More Information
05:22 EDTNEMNewmont Mining signs agreement to sell stake in Penmont JV in Mexico for $477M
Subscribe for More Information
September 11, 2014
10:20 EDTSRPTNebraska Medical Center not naming Ebola drug, The Street reports
Nebraska Medical Center is not releasing the name of the experimental Ebola drug being given to Dr. Rick Sacra, The Street's Adam Feuerstein reports, citing an emailed response from the hospital. Traders are speculating Tekmira (TKMR) is the manufacturer of the drug, Feuerstein points out. Sarepta (SRPT) disclosed that it is not involved in the treatment of Sacra, added Feuerstein. Shares of Tekmira are up 3% to $19.65 in morning trading. Reference Link
09:31 EDTTEVATeva announces new data from Phase IIIb GLACIER study
Subscribe for More Information
06:03 EDTACTGAcacia Research subsidiary reaches settlement with Fujitsu Network Communication
Subscribe for More Information
05:57 EDTAMDStocks with implied volatility above IV index mean; AMD RH
Subscribe for More Information
03:27 EDTTEVATeva Canada announces launch of generic version of Cipralex
Subscribe for More Information
September 10, 2014
15:21 EDTAZNAstraZeneca has a conference call hosted by JPMorgan
Subscribe for More Information
14:25 EDTTEVATeva Canada announces launch of generic version of Cipralex
Subscribe for More Information
10:44 EDTMUMicron mentioned positively at Raymond James
September 9, 2014
10:45 EDTAMDAMD says gaining share in commercial PC market is goal
The company is looking to "move up the stack" in the consumer PC space. Comments made at Deutsche Bank Technology Conference.
10:10 EDTNEMOn the Fly: Analyst Upgrade Summary
Subscribe for More Information
07:26 EDTAMDDeutsche Bank to hold a conference
Technology Conference to be held in Las Vegas on September 9-11 with webcasted company presentations to begin on September 9 at 10:30 am; not all company presentations may be webcasted. Webcast Link
07:22 EDTMURaymond James to hold a conference
North American Equities Conference to be held in London, England on September 9.
06:09 EDTNEMNewmont Mining upgraded to Outperform from Market Perform at Cowen
06:00 EDTAMDStocks with implied volatility top IV index mean; AMD YHOO
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use